Sustainable loading knob with features for improving torque transmission

Abstract

A sustainable loading knob (D) for multidose medicament delivery devices, featuring a cylindrical body with protruding wings (WD) for improved torque 5 transmission. The ergonomic design reduces force requirements for spring loading, enhances usability, and minimizes material use and packaging dimensions, providing an environmentally friendly solution for medicament delivery.

Description

[0001] Sustainable Loading Knob with Features for Improving Torque Transmission

[0002] TECHNICAL FIELD

[0003] The present invention relates to medicament delivery devices, particularly to pen injectors for multiple-dose medicament delivery. More specifically, it relates to a novel design of a loading knob that improves torque transmission for spring-assisted pen injectors while minimizing environmental impact.

[0004] BACKGROUND

[0005] Pen injectors and autoinjectors are widely used in medicament delivery systems. Pen injectors are often utilized for administering small doses of medicaments, such as insulin, while autoinjectors are preferred for single, larger doses. However, as new medicaments requiring larger delivery volumes emerge, such as those for metabolic disorders, the sustainability of single-dose autoinjectors becomes a concern due to their high environmental impact.

[0006] Multi dose pen injectors with spring-assisted mechanisms present a sustainable alternative. These devices reduce material usage and transportation emissions by consolidating multiple doses into a single device.

[0007] Medicament cartridges designed for multiple doses are available in various volumes. Standard sizes include 1.5 mL and 3 mL, while larger options, such as 5 mL, 10 mL, and 20 mL, are also available. Although these cartridges typically have similar stroke lengths, their diameters vary. Larger diameters require stronger springs to generate sufficient pressure to deliver the medicament through the needle.

[0008] Additionally, patients generally prefer needles with smaller diameters (e.g., 32G) as they are less painful. However, small-diameter needles require higher pressure to ensure the medicament is delivered within an acceptable injection time, typically no more than 10 seconds for 1 mL.In multidose devices which enable a patient to set a dosing amount for a dose to be expelled, the spring (drive spring) must be loaded during a dose-setting process, prior to a medicament delivery. To accommodate patients with varying levels of strength, the spring-loading mechanism should be designed to minimize the effort required to wind the spring.

[0009] In some multidose devices where dosing amounts are set by the medicament delivery device, the spring (drive spring) must be loaded prior to a medicament delivery to enable expelling of the medicament doses.

[0010] The loading knobs on conventional pen injectors are typically cylindrical. To operate these knobs, patients must pinch the knob with their fingers and rotate it. As illustrated in Fig. 1, which schematically represents a conventional cylindrical knob A with a diameter 0A (for instance 10 mm), the knob requires a pinching force FP and a lateral force FL to rotate. The loading force FL is directly proportional to the pinching force Fp as expressed in the equation:

[0011] FL = u x Fp.

[0012] The loading torque is then calculated as:

[0013] Loading Torque = FL X 0A.

[0014] To reduce the physical effort required while maintaining the same loading torque, a conventional methods include increasing the diameter of the knob. As shown in Fig. 2, knob B has twice the diameter 0B of knob A, which halves the required lateral force and the pinching force while maintaining the same torque:

[0015] Loading torque = ¥2 FL X 0B.

[0016] However, increasing the diameter significantly raises material usage, weight, and packaging size, negatively affecting sustainability. This trade-off highlights the need for innovative designs that improve usability while minimizing environmental impact.SUMMARY

[0017] The present invention addresses these challenges by introducing a sustainable loading knob featuring protruding wings.

[0018] The invention is specified by the independent claim. Preferred embodiments are defined in the dependent claims.

[0019] The present disclosure relates to a multidose medicament delivery device, comprising:

[0020] - A spring mechanism configured to be loaded prior to a medicament delivery;

[0021] - A rotatable loading knob, operatively connected to the spring mechanism, configured to be rotated by a patient to load the spring mechanism,

[0022] wherein the knob has a generally cylindrical shape with at least two protruding wings extending radially outward from the cylindrical surface, wherein the wings are dimensioned and positioned to provide an ergonomic grip for the patient, the wings being configured to receive forces applied by the patient to facilitate rotation of the knob.

[0023] The knob according to the invention reduces the loading force without requiring a knob with a larger cylindrical body. Hence, the inventive design reduces material usage, enhances usability, and facilitates compact packaging, thereby decreasing the environmental footprint. Moreover, the present invention removes the requirement for a pinching force, thereby enhancing ease of use for the patient.

[0024] In a non-limiting embodiment, the device extends axially between a proximal end and a distal end and defines a device axis, the proximal end being the one pointing towards a dose delivery site during use of the medicament delivery device. The device axis more particularly can be a proximodistal axis.

[0025] In a non-limiting embodiment, the knob has a rotation axis, and the knob is configured to be rotated by the patient about the rotation axis.In a non-limiting embodiment, the knob is configured to be rotated about the device axis. Thus, the rotation axis of the knob is identical to the device axis.

[0026] In a non-limiting embodiment, a dosing amount for a dose of medicament to be expelled by the medicament delivery device is set by the medicament delivery device. More particularly, for each dose of medicament to be expelled by the medicament delivery device, the respective dosing amount is set by the medicament delivery device. This way, dosing amount errors caused by the patient can be avoided.

[0027] In a non-limiting embodiment, the knob comprises exactly two wings. Thus, the knob comprises two wings and no more than two wings.

[0028] In a non-limiting embodiment, the two wings are diametrically opposed on the cylindrical surface.

[0029] In a non-limiting embodiment, the wings of the knob are asymmetrically shaped, the shape being configured to provide a distinct tactile and visual indication to the patient of the intended direction of rotation for loading the spring mechanism. More precisely, each of the wings is shaped this way. In particular, each of the wings of the knob is shaped this way relative to any plane containing the rotation axis of the knob, especially relative to any radial plane, i.e. to any plane containing the device axis. The wings of the knob more specifically can be shaped this way in any cross-section through the wings perpendicular to the rotation axis of the knob with respect to any direction perpendicular to the rotation axis of the knob, and especially, the wings of the knob can be shaped this way in any cross-section through the wings perpendicular to the device axis with respect to any radial direction.

[0030] In a non-limiting embodiment, each asymmetrically shaped wing comprises:

[0031] - A radial surface facing against the direction of rotation, and

[0032] - A sloped surface facing in the direction of rotation, wherein more particularly, the sloped surface adjoins the radial surface.In particular, the radial surface can be aligned within ±25° parallel to a radial plane passing through where the radial surface and the sloped surface adjoin, more particularly within +250parallel to said radial plane. For example, the radial surface can be aligned by between +50and +20° relative to a radial plane passing through where the radial surface and the sloped surface adjoin.

[0033] In a non-limiting embodiment, the sloped surface is sloped relative to a plane circumferential with respect to the rotation axis of the knob.

[0034] In a non-limiting embodiment, the sloped surface is convexly sloped.

[0035] In a non-limiting embodiment, the cylindrical surface of the knob is textured. More particularly, the cylindrical surface of the knob comprises a texture with radially outwardly protruding features, wherein each of the wings radially protrudes each of said radially outwardly protruding features.

[0036] In a non-limiting embodiment, the cylindrical surface of the knob is smooth.

[0037] In a non-limiting embodiment, the spring mechanism comprises a spring which is a drive spring of the medicament delivery device, and loading the spring mechanism causes the drive spring to be loaded, i.e. to be tensioned.

[0038] In a non-limiting embodiment, the spring mechanism comprises a spring, and loading the spring mechanism causes an axial movement of one end of the spring relative to the other end of the spring to tension the spring.

[0039] Especially, the spring can be a compression spring, such as a helical compression spring.

[0040] In a non-limiting embodiment, the medicament delivery device comprises a plunger rod device configured to act on a plunger of a medicament container to expel medicament from the medicament container by moving towards proximally, wherein the spring mechanism is configured to drive the plunger rod device towards proximally to cause an expelling of medicament from themedicament container. Thus, energy exerted by the patient by rotating the knob to load the spring mechanism is stored in the spring mechanism and is subsequently used to force the plunger rod device towards distally for expelling a dose of medicament.

[0041] In a non-limiting embodiment, the spring mechanism comprises a torsion spring. More particularly, the torsion spring is loaded by the patient rotating the knob.

[0042] In a non-limiting embodiment, the spring mechanism comprises a compression spring, in particular a helical compression spring. More particularly, the compression spring is loaded by the patient rotating the knob.

[0043] In a non-limiting embodiment, the spring mechanism is designed to act on medicament cartridges ranging from l.smL to 20mL in volume.

[0044] In a non-limiting embodiment, the device is a pen injector or an autoinjector.

[0045] The terms “radial” or “radially” refer to a direction extending radially relative to an axis, and “rotation”, “rotational” and “rotationally” refer to rotation relative to the axis.

[0046] Generally, all terms used in the claims are to be interpreted according to their ordinary meaning in the technical field, unless explicitly defined otherwise herein. All references to a / an / the element, apparatus, member, component, means, etc. are to be interpreted openly as referring to at least one instance of the element, apparatus, member component, means, etc., unless explicitly stated otherwise.

[0047] BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Embodiments of the present disclosure will now be described by way of example only and with reference to the following accompanying drawings.Fig. 1 shows a top view of a conventional cylindrical loading knob design showing the forces required for operation.

[0049] Fig. 2 shows a top view of a loading knob with increased diameter to reduce required force but at the cost of additional material and packaging.

[0050] Fig. 3 shows a top view of a loading knob according to the invention, with protruding wings, illustrating reduced force requirements while minimizing material use.

[0051] Fig. 4 shows a top view of a loading knob according to the invention, with protruding wings designed to show the intended rotation direction for spring loading.

[0052] Fig. 5 shows a perspective view of the loading knob of Fig. 4.

[0053] DETAILED DESCRIPTION

[0054] The present invention, embodiments of which being illustrated in Fig. 3 to 5, relates to a multidose medicament delivery device, such as a pen injector or an autoinjector, having:

[0055] - A spring mechanism configured to be loaded prior to a medicament delivery;

[0056] - A rotatable loading knob (reference C in the embodiment of Fig. 3 - reference D in the embodiment of Fig. 4 and 5), operatively connected to the spring mechanism, configured to be rotated by a patient to load the spring mechanism.

[0057] The spring mechanism may comprise a torsion spring that is loaded during the dose-setting process. Besides that, the device is designed to accommodate medicament cartridges of varying volumes (e.g., l.smLto 20mL), ensuring versatility while maintaining consistent usability.The loading knob according to the present invention can be employed for various medicament delivery devices. Thus, only the parts relevant for carrying out the disclosure will be described in detail.

[0058] The knob C, D has a generally cylindrical shape with at least two protruding wings (reference Wc in the embodiment of Fig. 3 - reference WD in the embodiment of Fig. 4 and 5) extending radially outward from the cylindrical surface (reference Sc in the embodiment of Fig. 3 - reference SD in the embodiment of Fig. 4 and 5). Each wing is dimensioned to provide sufficient leverage, reducing the required rotational force FL to load the spring mechanism. The wings must be sufficiently large and long to allow the patient’s fingers to grip them comfortably without requiring a pinching force.

[0059] In the non-limitative embodiments illustrated in Fig. 3 to 5, the knob C, D has 2 wings Wc, WD that are diametrically opposed to each other relative to a symmetrical axis of the cylindrical shape Sc, SD. The wings are configured to receive forces applied by the patient to facilitate rotation of the knob, reducing the effort required for spring loading compared to a similar knob of the same diameter but without wings.

[0060] The key advantages include an increased knob span, which effectively halves the required lateral force to ¥2 FL for the same torque, and the elimination of the need for the patient to pinch the knob, thereby enabling more efficient transfer of loading torque from the wrist to the knob. The design simplifies spring loading for patients, particularly those with limited hand strength.

[0061] In the non-limitative embodiments illustrated in Figures 3 to 5, the cylindrical surface Sc, SD of the knob C, D is provided with an optional textured surface (reference Tc in the embodiment of Fig. 3 - reference TD in the embodiment of Fig. 4 and 5). The textured surface Tc, TD is made for instance of a succession of grooves or teeths, and is designed to facilitate the grip of the device. Alternatively, the cylindrical surface Sc, SD may be smooth.In the embodiment of Fig. 4, the wings WD are asymmetrically shaped to guide the patient in the correct rotation direction. The asymmetrical shape aims at providing a distinct tactile and visual indication to the patient of the intended direction of rotation for loading the spring mechanism. More specifically, each asymmetrically shaped wing WD comprises:

[0062] - A radial surface RD facing against the direction of rotation, providing tactile resistance, and

[0063] - A sloped surface SLD facing in the direction of rotation, ensuring an intuitive and efficient loading motion.

[0064] This design guides the patient to apply force on the radial surfaces RD to achieve proper rotation of the knob D. This asymmetry not only ensures proper function but also improves the overall patient experience by reducing confusion and physical strain. In the example of Fig. 4, the radial surface RD is aligned by about +16° relative to a radial plane passing through where the radial surface and the sloped surface adjoin. The sign of the angle is given by the intended direction of rotation for loading the spring mechanism, i.e. for spring loading.

[0065] Key advantages include:

[0066] - Reduced Plastic Use: The winged design minimizes material while maintaining functionality.

[0067] - Compact Packaging: The wings allow for smaller overall device dimensions, reducing packaging volume and transport emissions. The wings allow compact packaging due to their minimal additional volume compared to increasing the cylindrical body diameter. This design allows packaging height to decrease by up to 50%, significantly increasing the number of devices transportable per pallet without increasing emissions.

[0068] - Enhanced Usability: Patients no longer need to pinch the knob, particularly beneficial for patients with limited dexterity.- Correct Rotation Direction: Asymmetrically shaped wings or markings ensure intuitive operation by guiding the patient to rotate the knob in the correct direction.

[0069] While the embodiments in Figures 3 to 5 focus on two wings, the design is adaptable to incorporate more wings or different shapes to meet specific ergonomic or functional requirements.

[0070] The delivery devices described herein can be used for the treatment and / or prophylaxis of one or more of many different types of disorders.

[0071] Exemplary disorders include, but are not limited to: rheumatoid arthritis, inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative colitis), hypercholesterolaemia and / or dyslipidemia, cardiovascular disease, diabetes (e.g. type 1 or 2 diabetes), psoriasis, psoriatic arthritis, spondyloarthritis, hidradenitis suppurativa, Sjogren's syndrome, migraine, cluster headache, multiple sclerosis, neuromyelitis optica spectrum disorder, anaemia, thalassemia, paroxysmal nocturnal hemoglobinuria, hemolytic anaemia, hereditary angioedema, systemic lupus erythematosus, lupus nephritis, myasthenia gravis, Behcet's disease, hemophagocytic lymphohistiocytosis, atopic dermatitis, retinal diseases (e.g., age-related macular degeneration, diabetic macular edema), uveitis, infectious diseases, bone diseases (e.g., osteoporosis, osteopenia), asthma, chronic obstructive pulmonary disease, thyroid eye disease, nasal polyps, transplant, acute hypoglycaemia, obesity, anaphylaxis, allergies, sickle cell disease, Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, systemic infusion reactions, immunoglobulin E (IgE)-mediated hypersensitivity reactions, cytokine release syndrome, immune deficiencies (e.g., primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy), enzyme deficiencies (e.g., Pompe disease, Fabry disease, Gaucher disease), growth factor deficiencies, hormone deficiencies, coagulation disorders (e.g., hemophilia, von Willebrand disease, Factor V Leiden), and cancer.Exemplary types of medicaments that could be included in the delivery devices described herein include, but are not limited to, small molecules, hormones, cytokines, blood products, enzymes, vaccines, anticoagulants, immunosuppressants, antibodies, antibody-medicament conjugates, neutralizing antibodies, reversal agents, radioligand therapies, radioisotopes and / or nuclear medicines, diagnostic agents, bispecific antibodies, proteins, fusion proteins, peptibodies, polypeptides, pegylated proteins, protein fragments, nucleotides, protein analogues, protein variants, protein precursors, protein derivatives, chimeric antigen receptor T cell therapies, cell or gene therapies, oncolytic viruses, or immunotherapies.

[0072] Exemplary medicaments that could be included in the delivery devices described herein include, but are not limited to, immuno-oncology or biooncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, coagulation factors, enzymes, enzyme inhibitors, retinoids, steroids, signaling proteins, pro-apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.

[0073] Exemplary medicaments that could be included in the delivery devices described herein include, but are not limited to, those exhibiting a proposed mechanism of action, such as human epidermal growth factor receptor 2 (HER-2) receptor modulators, interleukin (IL) modulators, interferon (IFN) modulators, complement modulators, glucagon-like peptide-i (GLP-i) modulators, glucose-dependent insulinotropic polypeptide (GIP) modulators, cluster of differentiation 38 (CD38) modulators, cluster of differentiation 22 (CD22) modulators, Ci esterase modulators, bradykinin modulators, C-C chemokine receptor type 4 (CCR4) modulators, vascular endothelial growth factor (VEGF) modulators, B-cell activating factor (BAFF), P-selectin modulators, neonatal Fc receptor (FcRn) modulators, calcitonin gene-related peptide (CGRP) modulators, epidermal growth factor receptor (EGFR) modulators, cluster of differentiation 79B (CD79B) modulators, tumor-associated calcium signal transducer 2 (Trop-2) modulators, cluster of differentiation 52 (CD52) modulators, B-cell maturation antigen (BCMA)modulators, enzyme modulators, platelet-derived growth factor receptor A (PDGFRA) modulators, cluster of differentiation 319 (CD319 or SLAMF7) modulators, programmed cell death protein 1 and programmed death-ligand 1 (PD-1 / PD-L1) inhibitors / modulators, B-lymphocyte antigen cluster of differentiation 19 (CD19) inhibitors, B-lymphocyte antigen cluster of differentiation 20 (CD20) modulators, cluster of differentiation 3 (CD3) modulators, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) modulators, T cell immunoreceptor with Ig and ITIM domains (TIGIT) modulators, V-domain Ig suppressor of T cell activation (VISTA) modulators, indoleamine 2,3-dioxygenase (IDO or INDO) modulators, poliovirus receptor-related immunoglobulin domain-containing protein (PVRIG) modulators, lymphocyte-activation gene 3 (LAG3; also known as cluster of differentiation 223 or CD223) antagonists, cluster of differentiation 276 (CD276 or B7-H3) antigen modulators, cluster of differentiation 47 (CD47) antagonists, cluster of differentiation 30 (CD30) modulators, cluster of differentiation 73 (CD73) modulators, cluster of differentiation 66 (CD66) modulators, cluster of differentiation W137 (CDW137) agonists, cluster of differentiation 158 (CD158) modulators, cluster of differentiation 27 (CD27) modulators, cluster of differentiation 58 (CD58) modulators, cluster of differentiation 80 (CD80) modulators, cluster of differentiation 33 (CD33) modulators, cluster of differentiation 159 (CD159 or NKG2) modulators, glucocorticoid-induced TNFR-related (GITR) protein modulators, Killer Ig-like receptor (KIR) modulators, growth arrest-specific protein 6 (GAS6) / AXL pathway modulators, A proliferation-inducing ligand (APRIL) receptor modulators, human leukocyte antigen (HLA) modulators, epidermal growth factor receptor (EGFR) modulators, B-lymphocyte cell adhesion molecule modulators, cluster of differentiation W123 (CDwi23) modulators, Erbb2 tyrosine kinase receptor modulators, endoglin modulators, mucin modulators, mesothelin modulators, hepatitis A virus cellular receptor 2 (HAVCR2) antagonists, cancer-testis antigen (CTA) modulators, tumor necrosis factor receptor superfamily, member 4 (TNFRSF4 or 0X40) modulators, adenosine receptor modulators, inducible T cell co-stimulator(ICOS) modulators, cluster of differentiation 40 (CD40) modulators, tumorinfiltrating lymphocytes (TIL) therapies, or T-cell receptor (TCR) therapies.

[0074] Exemplary medicaments that could be included in the delivery devices described herein include, but are not limited to: etanercept, abatacept, adalimumab, evolocumab, exenatide, secukinumab, erenumab, galcanezumab, fremanezumab-vfrm, alirocumab, methotrexate (amethopterin), tocilizumab, interferon beta-ia, interferon beta-ib, peginterferon beta-ia, sumatriptan, darbepoetin alfa, belimumab, sarilumab, semaglutide, dupilumab, reslizumab, omalizumab, glucagon, epinephrine, naloxone, insulin, amylin, vedolizumab, eculizumab, ravulizumab, crizanlizumab-tmca, certolizumab pegol, satralizumab, denosumab, romosozumab, benralizumab, emicizumab, tildrakizumab, ocrelizumab, ofatumumab, natalizumab, mepolizumab, risankizumab-rzaa, ixekizumab, and immune globulins.

[0075] Exemplary medicaments that could be included in the delivery devices described herein may also include, but are not limited to, oncology treatments such as ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, rituximab, trastuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan-nxki, pertuzumab, transtuzumab-pertuzumab, alemtuzumab, belantamab mafodotin-blmf, bevacizumab, blinatumomab, brentuximab vedotin, cetuximab, daratumumab, elotuzumab, gemtuzumab ozogamicin, 90-Yttrium-ibritumomab tiuxetan, isatuximab, mogamulizumab, moxetumomab pasudotox, obinutuzumab, ofatumumab, olaratumab, panitumumab, polatuzumab vedotin, ramucirumab, sacituzumab govitecan, tafasitamab, or margetuximab.

[0076] Exemplary medicaments that could be included in the delivery devices described herein include “generic” or biosimilar equivalents of any of the foregoing, and the foregoing molecular names should not be construed as limiting to the “innovator” or “branded” version of each, as in the nonlimiting example of innovator medicament adalimumab and biosimilars suchas adalimumab-afzb, adalimumab-atto, adalimumab-adbm, and adalimumab-adaz.

[0077] Exemplary medicaments that could be included in the delivery devices described herein also include, but are not limited to, those used for adjuvant or neoadjuvant chemotherapy, such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid. Exemplary chemotherapy medicaments include, by way of example but not limitation, 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, doxorubicin, daunorubicin, idarubicin, epirubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide, azacitidine, decitabine, bendamustine, bleomycin, bortezomib, busulfan, cabazitaxel, carmustine, cladribine, cytarabine, dacarbazine, etoposide, fludarabine, gemcitabine, irinotecan, leucovorin, melphalan, methotrexate, pemetrexed, mitomycin, mitoxantrone, temsirolimus, topotecan, valrubicin, vincristine, vinblastine, or vinorelbine.

[0078] Exemplary medicaments that could be included in the delivery devices described herein also include, but are not limited to, analgesics (e.g., acetaminophen), antipyretics, corticosteroids (e.g. hydrocortisone, dexamethasone, or methylprednisolone), antihistamines (e.g., diphenhydramine or famotidine), antiemetics (e.g., ondansetron), antibiotics, antiseptics, anticoagulants, fibrinolytics (e.g., recombinant tissue plasminogen activator [r-TPA]), antithrombolytics, or diluents such as sterile water for injection (SWFI), 0.9% Normal Saline, 0.45% normal saline, 5% dextrose in water, 5% dextrose in 0.45% normal saline, Lactated Ringer’s solution, Heparin Lock Flush solution, 100 U / mL Heparin Lock Flush Solution, or 5000 U / mL Heparin Lock Flush Solution.

[0079] Pharmaceutical formulations including, but not limited to, any medicament described herein are also contemplated for use in the delivery devices described herein, for example pharmaceutical formulations comprising a medicament as listed herein (or a pharmaceutically acceptable salt of the medicament) and a pharmaceutically acceptable carrier. Such formulationsmay include one or more other active ingredients (e.g., as a combination of one or more active medicaments), or may be the only active ingredient present, and may also include separately administered or co-formulated dispersion enhancers (e.g. an animal-derived, human-derived, or recombinant hyaluronidase enzyme), concentration modifiers or enhancers, stabilizers, buffers, or other excipients.

[0080] Exemplary medicaments that could be included in the delivery devices described herein include, but are not limited to, a multi-medication treatment regimen such as AC, Dose-Dense AC, TCH, GT, EC, TAC, TC, TCHP, CMF, FOLFOX, mF0LF0X6, mFOLFOXy, FOLFCIS, CapeOx, FLOT, DCF, FOLFIRI, FOLFIRINOX, FOLFOXIRI, IROX, CHOP, R-CHOP, RCHOP-21, Mini-CHOP, Maxi-CHOP, VR-CAP, Dose-Dense CHOP, EPOCH, Dose-Adjusted EPOCH, R-EPOCH, CODOX-M, IVAC, HyperCVAD, R-HyperCVAD, SC-EPOCH-RR, DHAP, ESHAP, GDP, ICE, MINE, CEPP, CDOP, GemOx, CEOP, CEPP, CHOEP, CHP, GCVP, DHAX, CALGB 8811, HIDAC, MOpAD, 7 + 3, 5 +2, 7 + 4, MEC, CVP, RBAC500, DHA-Cis, DHA-Ca, DHA-Ox, RCVP, RCEPP, RCEOP, CMV, DDMVAC, GemFLP, ITP, VIDE, VDC, VAI, VDC-IE, MAP, PCV, FCR, FR, PCR, HDMP, OFAR, EMA / CO, EMA / EP, EP / EMA, TP / TE, BEP, TIP, VIP, TPEx, ABVD, BEACOPP, AVD, Mini-BEAM, IGEV, C-MOPP, GCD, GEMOX, CAV, DT-PACE, VTD-PACE, DCEP, ATG, VAC, VelP, OFF, GTX, CAV, AD, MAID, AIM, VAC-IE, ADOC, or PE.

[0081] Various modifications to the embodiments described are possible and will occur to those skilled in the art without departing from the invention which is defined by the following claims.

Claims

Claims1. A multidose medicament delivery device, comprising:- A spring mechanism configured to be loaded prior to a medicament delivery;- A rotatable loading knob (C, D), operatively connected to the spring mechanism, configured to be rotated by a patient to load the spring mechanism,wherein the knob (C, D) has a generally cylindrical shape with at least two protruding wings (Wc, WD) extending radially outward from the cylindrical surface (Sc, SD),wherein the wings (Wc, WD) are dimensioned and positioned to provide an ergonomic grip for the patient, the wings (Wc, WD) being configured to receive forces applied by the patient to facilitate rotation of the knob, wherein the wings (WD) of the knob (D) are asymmetrically shaped, the shape being configured to provide a distinct tactile and visual indication to the patient of the intended direction of rotation for loading the spring mechanism.

2. The multidose medicament delivery device according to claim 1, wherein the knob (C, D) comprises exactly two wings (Wc, WD).

3. The multidose medicament delivery device according to claim 2, wherein the two wings (Wc, WD) are diametrically opposed on the cylindrical surface (Sc, SD).

4. The multidose medicament delivery device according to any of the preceding claims, wherein each asymmetrically shaped wing (WD) comprises:- A radial surface (RD) facing against the direction of rotation, and - A sloped surface (SLD) facing in the direction of rotation.

5. The multidose medicament delivery device according to any of the preceding claims, wherein the cylindrical surface (Sc, SD) of the knob (C, D) is textured.

6. The multidose medicament delivery device according to any of claims 1 to 4, wherein the cylindrical surface (Sc, SD) of the knob (C, D) is smooth.

7. The multidose medicament delivery device according to any of the preceding claims, wherein the spring mechanism comprises a torsion spring.

8. The multidose medicament delivery device according to any of the preceding claims, wherein the spring mechanism is designed to act on medicament cartridges ranging from l.smL to 20mL in volume.

9. The multidose medicament delivery device according to any of the preceding claims, wherein the device is a pen injector or an autoinjector.

10. A kit comprising:- a multidose medicament delivery device according to any of the preceding claims; and- a storage box for said medicament delivery device.

Images